biostudies-literatureAvelino-Silva VINHLBINHLBI NIH HHS107222https://www.ebi.ac.uk/biostudies/studies/S-EPMC11569788biostudies-literatureUnknown148<h4>Background</h4>Exposure to antiretrovirals at or early after HIV acquisition can suppress viral replication and blunt antibody (Ab) responses; a reduced HIV detectability could impact diagnosis and blood donation screening.<h4>Methods</h4>We used three antigen (Ag)/Ab assays and one nucleic acid test (NAT) to analyze samples collected in pre-exposure prophylaxis (PrEP) trials (iPrEx; Partners PrEP) before infection detection by Ab-only rapid diagnostic tests (RDTs), and in early antiretroviral treatment (ART) initiation studies (RV254; SIPP).<h4>Results</h4>Reactivity using NAT and Ag/Ab assays in samples collected up to 8 weeks prior to the first reactive RDT from 251 PrEP trials participants varied between 49-61% for active PrEP users and between 27-37% for placebo users. Among RV254International journal of infectious diseases : IJID : official publication of the International Society for Infectious DiseasesSuppressed HIV antibody responses following exposure to antiretrovirals-evidence from PrEP randomized trials and early antiretroviral treatment initiation studies.PMC1156978875N92019D0003375N92019D00032de Souza MGrebe ELingappa JRAkapirat SConway ALVasan SNorris PJAvelino-Silva VIKleinman SHSacdalan CNHLBI Recipient Epidemiology and Donor Evaluation Study-IV-Pediatric (REDS-IV-P)Schmidt MDefechereux PStone MCuster BBusch MPBakkour SMehrotra MFacente SDi Germanio CWright DGrant RMPhanuphak NDeng XfalseSuppressed HIV antibody responses following exposure to antiretrovirals-evidence from PrEP randomized trials and early antiretroviral treatment initiation studies.<h4>Background</h4>Exposure to antiretrovirals at or early after HIV acquisition can suppress viral replication and blunt antibody (Ab) responses; a reduced HIV detectability could impact diagnosis and blood donation screening.<h4>Methods</h4>We used three antigen (Ag)/Ab assays and one nucleic acid test (NAT) to analyze samples collected in pre-exposure prophylaxis (PrEP) trials (iPrEx; Partners PrEP) before infection detection by Ab-only rapid diagnostic tests (RDTs), and in early antiretroviral treatment (ART) initiation studies (RV254; SIPP).<h4>Results</h4>Reactivity using NAT and Ag/Ab assays in samples collected up to 8 weeks prior to the first reactive RDT from 251 PrEP trials participants varied between 49-61% for active PrEP users and between 27-37% for placebo users. Among RV2542024-01-01T00:00:00Z2024 Nov2025-04-04T00:48:12.64Z2025-04-04T00:48:12.64ZS-EPMC115697883918696910.1016/j.ijid.2024.107222